Deferasirox (201530-41-8)

  • For any enquiries about this API or any of Tofigh Daru’s other products, please contact:
  • Contact Us >>

Product Detail

Mechanism:

Deferasirox works in treating iron toxicity by binding trivalent (ferric) iron (for which it has a strong affinity), forming a stable complex which is eliminated via the kidneys. It is selective for iron (as Fe3+) and is a tridentate ligand that binds iron with high affinity in a 2:1 ratio. Although deferasirox has very low affinity for zinc and copper there are variable decreases in the serum concentration of these trace metals after the administration of deferasirox. The clinical significance of these decreases is uncertain.

Packaging: Polyethylene nylon plastic bag

Storage conditions: Room Temprature

CAS Number:  201530-41-8

Formula:  C21H15N3O4

Molecular Weight: 373.362  g/mol

Method of Analysis:  in house monograph

Application:

Deferasirox is a synthetic, orally bioavailable, achiral, tridentate triazole derived from salicylic acid with iron-chelating activity. Its main use is to reduce chronic iron overload in patients who are receiving long term blood transfusions for conditions such as beta-thalassemia and other chronic anemias. It is the first oral medication approved in the USA for this purpose. It chelates iron at a 2:1 (ligand:iron) ratio. Because of its oral availability and long plasma half-life, this agent may be superior to desferrioxamine , which is orally inactive and has a short plasma half-life.